Aeglea BioTherapeutics, Inc. (AGLE) News
Filter AGLE News Items
AGLE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AGLE News Highlights
- For AGLE, its 30 day story count is now at 3.
- Over the past 2 days, the trend for AGLE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest AGLE News From Around the Web
Below are the latest news stories about AEGLEA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate AGLE as an investment opportunity.
Aeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsAeglea BioTherapeutics ( NASDAQ:AGLE ) First Quarter 2023 Results Key Financial Results Net loss: US$18.4m (loss... |
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue EstimatesAeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Aeglea BioTherapeutics Reports First Quarter 2023 Financial ResultsAeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial results for the first quarter 2023. |
Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study FailsAeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news. |
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic AlternativesAeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases, today announced interim results from the ongoing Phase 1/2 clinical trial of pegtarviliase, a novel recombinant human enzyme engineered to reduce elevated levels of total homocysteine, for the treatment of Classical Homocystinuria. Following its review of the interim results, the company announced that it is exploring strategic al |
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue EstimatesAeglea (AGLE) delivered earnings and revenue surprises of 10% and 1.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program UpdatesAeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates. |
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) insiders placed bullish bets worth US$695k in the last 12 monthsGenerally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off Friday with an overview of the biggest pre-market stock movers traders will want to keep an eye on today! |
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational EfficiencyAeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced an update to its corporate structure. These changes are in addition to the restructuring process that was initiated in August 2022 and are intended to further streamline the organization, create operational efficiencies to support near- and long-term objectives and maximize the value of the |